Payment overview · 2025
General Payments
$2,398.61
148 reported records · 29 companies
Healthcare provider profile · identity verified
Thomas Hamilton, DO
Allopathic & Osteopathic Physicians|Family Medicine · TOPEKA, KS · NPI 1871592246
Verified facts
What the public records show
CMS Open Payments records show Thomas Hamilton, DO received $2,398.61 in general payments during 2025 across 148 reported records.
PFIZER INC. accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 58 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Jardiance by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nucynta as an associated drug or biological on 230 records involving 95 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nucynta by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $339.16 | 14.1% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $270.70 | 11.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $259.58 | 10.8% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $251.62 | 10.5% | 22 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $235.58 | 9.8% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $172.00 | 7.2% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $154.62 | 6.5% | 16 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $92.41 | 3.9% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $83.69 | 3.5% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $82.20 | 3.4% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $53.45 | 2.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.13 | 1.6% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $37.75 | 1.6% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.34 | 1.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.07 | 1.4% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $29.58 | 1.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.23 | 1.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.58 | 0.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.14 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.11 | 0.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.90 | 0.8% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $17.07 | 0.7% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $16.22 | 0.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.84 | 0.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.81 | 0.7% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.27 | 0.6% | 1 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $15.24 | 0.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.71 | 0.6% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.61 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,398.61 | 148 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $254.09 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $236.27 | 10 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $236.27 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $195.14 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $195.14 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $190.73 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $165.08 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $154.57 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $153.41 | 17 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $128.34 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $99.84 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $93.34 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $92.41 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $88.11 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.90 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $84.21 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $83.69 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $82.20 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $78.66 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $77.70 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $77.03 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.51 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.68 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.74 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $61.33 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $53.45 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $52.09 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $39.13 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $37.75 | 2 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $36.34 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $29.58 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.32 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.23 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $27.23 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $27.23 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $22.26 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| Orbactiv Normalized: orbactiv |
Drug | Melinta Therapeutics, LLC | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $12.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 100 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 185 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 228 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 165 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
185 | 35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
228 | 42 |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | Nucynta open payments reported associated product |
CMS Open Payments — General Payments 230 supporting records · 95 recipient NPIs · example record 1224105108 |
Nucynta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
228 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
165 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1073 | 290 |
| Levothyroxine Sodium | Levothyroxine Sodium | 704 | 168 |
| Pantoprazole Sodium | Pantoprazole Sodium | 439 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 418 | 110 |
| Valsartan | Valsartan | 365 | 92 |
| Gabapentin | Gabapentin | 337 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 93 |
| Lisinopril | Lisinopril | 322 | 86 |
| Tramadol Hcl | Tramadol Hcl | 310 | 64 |
| Losartan Potassium | Losartan Potassium | 283 | 78 |
| Omeprazole | Omeprazole | 280 | 75 |
| Jardiance | Empagliflozin | 228 | 42 |
| Allopurinol | Allopurinol | 227 | 56 |
| Furosemide | Furosemide | 215 | 47 |
| Carvedilol | Carvedilol | 198 | 50 |
| Potassium Chloride | Potassium Chloride | 196 | 48 |
| Metformin Hcl Er | Metformin Hcl | 192 | 52 |
| Farxiga | Dapagliflozin Propanediol | 185 | 35 |
| Celecoxib | Celecoxib | 171 | 44 |
| Sertraline Hcl | Sertraline Hcl | 170 | 38 |
| Ozempic | Semaglutide | 165 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 43 |
| Pioglitazone Hcl | Pioglitazone Hcl | 143 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 35 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 128 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 33 |
| Clonazepam | Clonazepam | 121 | 16 |
| Montelukast Sodium | Montelukast Sodium | 121 | 30 |
| Trazodone Hcl | Trazodone Hcl | 120 | 36 |
| Metformin Hcl | Metformin Hcl | 116 | 33 |
| Simvastatin | Simvastatin | 106 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 29 |
| Ibandronate Sodium | Ibandronate Sodium | 103 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 22 |
| Eliquis | Apixaban | 100 | 23 |
| Glimepiride | Glimepiride | 100 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 31 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 91 | 21 |
| Ezetimibe | Ezetimibe | 91 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 88 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 86 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 84 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 81 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 23 |
| Mounjaro | Tirzepatide | 77 | 16 |
| Bupropion Xl | Bupropion Hcl | 75 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 75 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 22 |
| Meloxicam | Meloxicam | 73 | 22 |
| Finasteride | Finasteride | 70 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 12 |
| Synthroid | Levothyroxine Sodium | 69 | 12 |
| Donepezil Hcl | Donepezil Hcl | 68 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 68 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 15 |
| Spironolactone | Spironolactone | 67 | 24 |
| Telmisartan | Telmisartan | 67 | 17 |
| Fenofibrate | Fenofibrate | 65 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 20 |
| Memantine Hcl | Memantine Hcl | 61 | suppressed |
| Alprazolam | Alprazolam | 60 | 13 |
| Fenofibrate | Fenofibrate,micronized | 60 | 16 |
| Topiramate | Topiramate | 59 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 58 | 22 |
| Nateglinide | Nateglinide | 57 | 15 |
| Dutasteride | Dutasteride | 56 | 14 |
| Pregabalin | Pregabalin | 56 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 20 |
| Lorazepam | Lorazepam | 55 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 54 | 14 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 52 | 16 |
| Buspirone Hcl | Buspirone Hcl | 50 | 12 |
| Irbesartan | Irbesartan | 46 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 43 | suppressed |
| Estradiol | Estradiol | 42 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 38 | suppressed |
| Torsemide | Torsemide | 36 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 25 |
| Temazepam | Temazepam | 32 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 21 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Diazepam | Diazepam | 26 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Rifampin | Rifampin | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Galantamine Er | Galantamine Hbr | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nucynta | Tapentadol Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Linezolid | Linezolid | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Methadone Hcl | Methadone Hcl | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Humira(Cf) Pen | Adalimumab | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,398.61 · 148 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, BEXSERO, BOTOX, BREZTRI, Belbuca, CAMZYOS, CAPLYTA, CAPVAXIVE, COMIRNATY, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, IBSRELA, Integra, Integra Dermal Regeneration Template, JARDIANCE, Kerecis GraftGuide, Kerecis SurgiClose, Kimyrsa, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Orbactiv, Ozempic, PAXLOVID, PREVNAR 20, PRIMATRIX, PROLIA, QULIPTA, Qelbree, REPATHA, REXULTI, ROTATEQ, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, UNITHROID, VAXELIS, VAXNEUVANCE, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error